Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 38.7849
- Book/Share 33.5765
- PB 7.3218
- Debt/Equity 0.5878
- CurrentRatio 1.0277
- ROIC 0.1371
- MktCap 592449554426.0
- FreeCF/Share 8.1108
- PFCF 30.0766
- PE 22.2745
- Debt/Assets 0.2406
- DivYield 0.0209
- ROE 0.3378
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Morgan Stanley | Equal Weight | Overweight | -- | $262 | Jan. 28, 2026 |
| Initiation | JNJ | Scotiabank | -- | Sector Outperform | -- | $230 | Nov. 13, 2025 |
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
Published: February 23, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Read More
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
Johnson & Johnson is a core player in global healthcare. A diverse portfolio, fortress-like balance sheet, and industry tailwinds cement a growing dividend.
Read More
Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility
Published: February 19, 2026 by: Fox Business
Sentiment: Positive
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.
Read More
2 High-Yield CEFs To Enhance Your Retirement Income
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Positive
2 High-Yield CEFs To Enhance Your Retirement Income
Read More
Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory
Published: February 18, 2026 by: WSJ
Sentiment: Positive
The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
Read More
J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push
Published: February 18, 2026 by: Reuters
Sentiment: Positive
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing amid President Donald Trump's tariff threats.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
Published: February 18, 2026 by: 24/7 Wall Street
Sentiment: Positive
Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different.
Read More
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues.
Read More
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
Published: February 13, 2026 by: Reuters
Sentiment: Negative
A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to an attorney for plaintiffs in nationwide talc litigation against the company.
Read More
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within its pharmaceuticals division, called Innovative Medicine. The company has several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension (PH) and infectious diseases.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
The Big 3: JNJ, XOM, KO
Published: February 05, 2026 by: Schwab Network
Sentiment: Neutral
Thursday's trading action is what Dan Deming calls a "tummy tester" with tech taking another gut punch and Bitcoin dropping to November 2024 lows. Dan turns to defensive stocks for his Big 3, offering example options trades for Johnson & Johnson (JNJ), Exxon Mobil (XOM), and Coca-Cola (KO).
Read More
What's Behind The 50% Surge In JNJ Stock?
Published: February 03, 2026 by: Forbes
Sentiment: Positive
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)'s stock experienced a remarkable 52% increase, driven by improved earnings, significant product achievements, and advancements in legal matters. Behind this 3.2% uplift in revenue and enhancement in margins is a narrative of innovation, effective risk management, and strategic evolution—let's delve into what has influenced this change.
Read More
Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
World's #1 Selling Contact Lens Brand ACUVUE®*1 Brings Pioneering Innovation For Astigmatic Patients With Presbyopia, Providing Visual Clarity And Comfort**2
Read More
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Negative
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Read More
This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks
Published: January 29, 2026 by: Barrons
Sentiment: Positive
Susan Bao's large-cap JPMorgan fund has outperformed the S&P 500 over many years. She's bullish on stocks, focused on bargains.
Read More
Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.
Read More
Johnson & Johnson: Strong Momentum Heading Into 2026
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange for lower drug prices. This is expected to provide gross margin relief despite some remaining pressure. Guidance for 2026 calls for accelerating top-line growth and at least 50bps pre-tax operating margin expansion. They also have longer-term double-digit growth ambitions.
Read More
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth indication for DARZALEX FASPRO ® and fifth in the newly diagnosed setting, underscoring its role as foundational therapy for both newly diagnosed and relapsed/refractory multiple myeloma patients HORSHAM, Pa., Jan. 27, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who …
Read More
J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson JNJ announced its financial outlook for 2026, which exceeded consensus expectations.
Read More
The 3 Dividend Stocks I Think Every Investor Should Own Right Now
Published: January 26, 2026 by: 24/7 Wall Street
Sentiment: Positive
The current macro investing climate is one in which investors have plenty to consider.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.
Read More
Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
Published: January 23, 2026 by: MarketBeat
Sentiment: Neutral
Johnson & Johnson NYSE: JNJ, amid the noise of Trump's Greenland agenda and renewed trade war fears, is quietly executing its healthcare strategy, growing revenue and widening margins, setting its stock up to continue trending higher. A recent earnings release and 2026 guidance update, though strong, triggered a price pullback and a trend-following opportunity.
Read More
Goldman Sachs Says Correction Could Be Coming: 5 Safe Dividend Stocks From the Conviction List
Published: January 23, 2026 by: 24/7 Wall Street
Sentiment: Positive
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest U.S.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100